整群随机交叉试验的报告质量:报告条目建议及报告质量评估
该研究系统检索MEDLINE、EMBASE和CINAHL Plus至2014年12月,纳入83项整群随机交叉(CRXO)试验,评估其报告质量。结果显示仅7项(8%)在标题中标识为整群随机交叉、21项(25%)在摘要中标识,仅20项(24%)提供设计理由,17项(20%)讨论携带效应,58%(48项)报告样本量方法,23%(19项)分析方法报告不充分,无任何试验报告主要结局的组内期间内和组内期间间组内相关系数。作者认为需改进CRXO试验报告质量并制定CONSORT扩展版。
要点
- 83项CRXO试验中,仅7项(8%)在标题、21项(25%)在摘要中标识为整群随机交叉设计。
- 仅20项(24%)提供设计理由,17项(20%)讨论携带效应,58%(48项)报告样本量方法。
- 23%(19项)分析方法报告不充分,无任何试验报告主要结局的组内期间内和组内期间间组内相关系数。
核心结论
- CRXO试验的报告质量明确需要改进,鉴于其独特特征,有必要制定CONSORT扩展版,且试验者之间就该指南内容达成共识至关重要。
研究设计与样本
- 对CRXO试验进行系统综述,检索MEDLINE、EMBASE、CINAHL Plus及CRXO方法学文章的引文检索,截至2014年12月。
- 数据库检索共识别3425条记录,83项试验符合纳入标准。
- 报告质量依据2010年CONSORT和2012年整群试验扩展版的修改条目及其他建议的质量指标进行评估。
主要发现
- 在标题中标识为「整群随机交叉」的试验为7项(8%),在摘要中标识的为21项(25%),提供设计理由的为20项(24%)。
- 设计参数如集群数和期数报告良好;讨论携带效应的仅17项(20%)。
- 样本量方法仅在58%(48项)的试验中报告;分析方法在23%(19项)的试验中报告不充分。
- 主要结局数据的组内期间内组内相关系数和组内期间间组内相关系数在任何试验中均未报告。
- 选择偏倚、实施偏倚和检测偏倚的潜在风险可分别在30%、81%和70%的试验中评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The cluster randomised crossover (CRXO) design is gaining popularity in trial settings where individual randomisation or parallel group cluster randomisation is not feasible or practical. Our aim is to stimulate discussion on the content of a reporting guideline for CRXO trials and to assess the reporting quality of published CRXO trials. METHODS: We undertook a systematic review of CRXO trials. Searches of MEDLINE, EMBASE, and CINAHL Plus as well as citation searches of CRXO methodological articles were conducted to December 2014. Reporting quality was assessed against both modified items from 2010 CONSORT and 2012 cluster trials extension and other proposed quality measures. RESULTS: Of the 3425 records identified through database searching, 83 trials met the inclusion criteria. Trials were infrequently identified as "cluster randomis(z)ed crossover" in title (n = 7, 8%) or abstract (n = 21, 25%), and a rationale for the design was infrequently provided (n = 20, 24%). Design parameters such as the number of clusters and number of periods were well reported. Discussion of carryover took place in only 17 trials (20%). Sample size methods were only reported in 58% (n = 48) of trials. A range of approaches were used to report baseline characteristics. The analysis method was not adequately reported in 23% (n = 19) of trials. The observed within-cluster within-period intracluster correlation and within-cluster between-period intracluster correlation for the primary outcome data were not reported in any trial. The potential for selection, performance, and detection bias could be evaluated in 30%, 81%, and 70% of trials, respectively. CONCLUSIONS: There is a clear need to improve the quality of reporting in CRXO trials. Given the unique features of a CRXO trial, it is important to develop a CONSORT extension. Consensus amongst trialists on the content of such a guideline is essential.
引用
- Arnup SJ, Forbes AB, Kahan BC, et al. The quality of reporting in cluster randomised crossover trials: proposal for reporting items and an assessment of reporting quality. Trials. 2016. PMID: 27923384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。